How many insider trades does FilingIQ track for TXG?

FilingIQ tracks 1,197 Form 4 insider transactions for TXG (10x Genomics, Inc.), covering filings from Sep 12, 2019 onwards. 13 of those were filed in the last 90 days.

Are TXG insiders net buyers or net sellers?

Across the full Form 4 history for TXG, 6 transactions (1%) were open-market purchases and 898 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TXG insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TXG in?

10x Genomics, Inc. (TXG) is classified in the Healthcare sector, specifically Health Information Services, with a current market capitalisation of $2.51B.

TXG insider trading

NasdaqGS Healthcare

10x Genomics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,197

Last 90 days

Buys / sells

1% / 75%

Market cap

$2.51B

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Company website: www.10xgenomics.com

TXG insider activity at a glance

FilingIQ has scored 1,197 insider transactions for TXG since Sep 12, 2019. The most recent filing in our index is dated Apr 14, 2026.

Across the full history, 6 open-market purchases and 898 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TXG insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TXG trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding TXG

Decheng Capital Management III (Cayman), LLC

$14.83M · 4.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for TXG?: FilingIQ tracks 1,197 Form 4 insider transactions for TXG (10x Genomics, Inc.), covering filings from Sep 12, 2019 onwards. 13 of those were filed in the last 90 days.
Are TXG insiders net buyers or net sellers?: Across the full Form 4 history for TXG, 6 transactions (1%) were open-market purchases and 898 (75%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TXG insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TXG in?: 10x Genomics, Inc. (TXG) is classified in the Healthcare sector, specifically Health Information Services, with a current market capitalisation of $2.51B.

Methodology & sources

Every TXG insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.